Related Experiment Video
Updated: Jun 22, 2026

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
Published on: August 18, 2023
Breast cancer and pregnancy: how safe is trastuzumab?
Hatem A Azim1, Fedro A Peccatori, Sarah J Liptrott
1Department of Medicine, European Institute of Oncology, Via Ripamonti 435, Milan, Italy.
Background:
A 29-year-old woman was diagnosed with lymph-node-positive, steroid-hormone-receptor-negative and HER2/neu-positive breast cancer. She underwent surgery followed by cyclophosphamide, epirubicin, and 5-fluorouracil chemotherapy, and received radiotherapy followed by trastuzumab therapy for 1 year. During the tenth month of trastuzumab therapy, the patient reported a missed period and had a positive pregnancy test.
Investigations:
Physical examination, pregnancy test, echocardiography.
Diagnosis:
Unintended pregnancy during adjuvant trastuzumab therapy.
Management:
Cessation of trastuzumab and close monitoring of mother and fetus during pregnancy.
More Related Videos
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Teratogenicity
Tumor Immunotherapy